Deals, Divestitures In Store As Dr Reddy’s Stays Course To Top 5 India League
Executive Summary
Investments in differentiated and specialty products and collaborations, alongside divestitures, are part of Dr Reddy’s plans as it seeks to move up the rankings in India. Momentum in China, including an alliance with Sunflower Pharma for orphan diseases, is also being keenly watched.
You may also be interested in...
India M&A Hourglass: Control Deals, ‘FOMO’, Monetization Calls At Family-Owned Firms
The founder and MD of investment bank Candle Partners reflects on key pharma M&A trends over the years and the shape of things to come including private equity action and how family-owned firms are weighing monetization and diversification options.
More Interest In Speculated Cipla Stake Sale: Portfolio, Cultural Fit Will Matter
After PEs, Torrent Pharma is speculated to be in the fray for a stake in Cipla. Experts weigh in on the contours of the product and cultural alignment of the two firms, should things move forward and also whether other Indian players could take a shot at the 'once in a lifetime opportunity'.
More Interest In Speculated Cipla Stake Sale: Portfolio, Cultural Fit Will Matter
After PEs, Torrent Pharma is speculated to be in the fray for a stake in Cipla. Experts weigh in on the contours of the product and cultural alignment of the two firms, should things move forward and also whether other Indian players could take a shot at the 'once in a lifetime opportunity'.